A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
← catalyst calendarNCT07763418 · readout in 117 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-24 | estimated | When the study began enrolling |
| Primary completion | 2026-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Failure, Chronic
Intervention
- Drug: Golcadomide — also filed as BMS-986369, CC-99282
Primary outcomes
what the primary-completion date above is the date OFMaximum observed concentration (Cmax)
measured Up to Day 44
Time of maximum observed plasma concentration (Tmax)
measured Up to Day 44
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
measured Up to Day 44
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
measured Up to Day 44
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed